Carmel Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Carmel Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32	Closed	-$14K	–	400
2023 Q3	$14K	Buy	+32	New	+$16K	0.01%	401

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carmel Capital Partners's IDXX Position: Q4 2023 in Review

Carmel Capital Partners sold out of Idexx Laboratories (IDXX) in Q4 2023, closing a stake of 32 shares — an estimated $14K sold.

Carmel Capital Partners first reported a position in IDXX in Q3 2023 and held it in 1 quarter. The position peaked at $14K in Q3 2023. 1,153 funds tracked by Wall St. Rank hold IDXX as of Q4 2023.

Carmel Capital Partners reported no remaining Idexx Laboratories position as of Q4 2023 after selling out during the quarter.
Carmel Capital Partners sold 32 Idexx Laboratories shares in Q4 2023, an estimated $14K.
Carmel Capital Partners first reported a position in Idexx Laboratories in Q3 2023 and held it in 1 quarter.
Carmel Capital Partners's Idexx Laboratories position peaked at $14K in Q3 2023.
1,153 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2023.

Based on Carmel Capital Partners's 13F filing for Q4 2023, filed 1 Feb 2024.